CMS is planning to examine and determine coverage for the first Alzheimer medication in decades for Biogen’s Aduhelm. However, the jury remains concerned about the efficacy of the medication. In early June, the medication received FDA clearance via an expedited route. The medication will have a wholesale price of $56,000, even if it does not have a proven benefit.

Read more at DistilINFO Healthplan